On the pharmacokinetics of latamoxef in normal and impaired renal function.
Pharmacokinetics of latamoxef (Moxalactam) have been investigated in 10 normal volunteers and 20 patients with impaired renal function after i.v. injection of 2 g. Elimination observed in normal volunteers can best be described by a two-compartment model. In the presence of impaired renal function elimination of latamoxef is markedly prolonged. The result is a larger area under the serum level curve (area under the curve; AUC). AUC and glomerular filtration rate (as well as AUC and plasma creatinine as approximate measure of renal function) can be brought into a mathematical relation. From these relations a dose reduction factor (DRF) can be derived. By means of this factor a dose can be calculated for each arbitrary degree of renal impairment which causes the same AUC that would be anticipated in a subject with normal renal function. Dosing proposals are given in tabular form. These allow to bring about, that in each conceivable degree of renal failure, an AUC would be reached as it would have been attained in normal subjects.
D003404:Creatinine / Q000097:blood; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008954:Models, Biological; D009070:Moxalactam / Q000008:administration & dosage / Q000378:metabolism*
D003404:Creatinine; D009070:Moxalactam